Dr. Lal PathLabs Ltd

Dr. Lal PathLabs Ltd has successfully completed the acquisition of a 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL) on May 01, 2026. This follows an earlier intimation dated April 30, 2026. With the completion of this transaction, SDCPL has become a Wholly Owned Subsidiary of Dr. Lal PathLabs. The necessary disclosures under SEBI regulations were previously provided. This strategic move is expected to enhance Dr. Lal PathLabs' presence and service offerings in the diagnostic sector.

Dr. Lal PathLabs Limited announced its consolidated financial results for Q4 FY26. The company reported a revenue of ₹703 Cr, marking a 16.6% growth. EBITDA for the quarter increased by 10.5% with a margin of 26.6%, while Profit After Tax (PAT) was ₹132 Cr, achieving an 18.8% margin. The board also declared a final dividend of 40%, equivalent to ₹4 per share. As of March 31, 2026, the company held ₹1,526 Cr in cash and cash equivalents. Dr. Lal PathLabs operates an extensive network across India, including 312 clinical laboratories, 7,727 Patient Service Centers, and 13,935 Pick-up Points, serving individual patients, hospitals, and corporate clients.

Dr. Lal PathLabs' Board of Directors approved the audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026. The board recommended a final dividend of ₹4 per equity share for FY26, with June 26, 2026, as the record date. Key strategic moves include the acquisition of a 100% stake in Shahbazkers Diagnostic Centre Private Limited, making it a wholly-owned subsidiary, and the incorporation of a new wholly-owned subsidiary, Dr. Lal PathLabs FZCO, in Dubai, UAE, for international expansion. Additionally, the board re-appointed (Hony) Brig. Dr. Arvind Lal as Executive Chairman and Mr. Rajit Mehta as an Independent Director. Dr. Reena Nakra and Dr. Saloni Khera were designated as Senior Management Personnel. The re-appointment of M/s Ernst & Young LLP as Internal Auditors and M/s A.G. Agarwal & Associates as Cost Auditors for FY27 was also approved. Finally, 82,750 equity shares were allotted under the Employee Stock Option Plan 2022.

Dr. Lal PathLabs Ltd. announced its Board of Directors' decisions from the meeting on April 30, 2026. The Board approved the Audited Standalone & Consolidated Financial Results for the Quarter and Financial Year ended March 31, 2026. A final dividend of INR 4/- per equity share (40% on face value of INR 10/-) was recommended for FY26, with June 26, 2026, as the record date. The company also approved the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL), making it a Wholly Owned Subsidiary. Furthermore, the incorporation of a new Wholly Owned Subsidiary, Dr. Lal PathLabs FZCO, in Dubai, UAE, was approved. The Board re-appointed Dr. Arvind Lal as Executive Chairman and Whole-Time Director and Mr. Rajit Mehta as a Non-Executive Independent Director. Dr. Reena Nakra and Dr. Saloni Khera were designated as Senior Management Personnel. M/s Ernst & Young LLP and M/s A.G. Agarwal & Associates were re-appointed as Internal and Cost Auditors, respectively. Lastly, 82,750 Equity Shares were allotted under the Employee Stock Option Plan 2022.

Dr. Lal PathLabs Ltd has designated Dr. Reena Nakra (Chief Scientific Officer) and Dr. Saloni Khera (Chief Lab Management Officer) as Senior Management Personnel (SMP) of the company, effective April 30, 2026. This decision was made during the Board of Directors meeting held on the same date, where other key matters were also approved, including financial results, dividend recommendation, acquisition of Shahbazkers Diagnostic Centre Private Limited, incorporation of a wholly-owned subsidiary in Dubai, and re-appointments of directors and auditors.

Dr. Lal PathLabs' Board approved audited financial results for Q4 and FY ended March 31, 2026. The board recommended a final dividend of INR 4/- per equity share (40%) for FY26, with June 26, 2026, as the record date. Key strategic moves include the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL), making it a wholly-owned subsidiary, and the incorporation of a new wholly-owned subsidiary, Dr. Lal PathLabs FZCO, in Dubai, UAE. Additionally, the board re-appointed Dr. Arvind Lal as Executive Chairman and Mr. Rajit Mehta as Non-Executive Independent Director for five years. Dr. Reena Nakra and Dr. Saloni Khera were designated as Senior Management Personnel. M/s Ernst & Young LLP and M/s A.G. Agarwal & Associates were re-appointed as Internal and Cost Auditors, respectively, for FY27. The company also allotted 82,750 equity shares under its ESOP 2022.

Dr. Lal PathLabs Ltd's board approved the audited financial results for the quarter and financial year ended March 31, 2026, and recommended a final dividend of ₹4 per equity share (40% on a face value of ₹10 each), subject to shareholder approval at the AGM. The record date for the dividend is June 26, 2026. The company will acquire 100% stake in Shahbazkers Diagnostic Centre Private Limited, making it a wholly-owned subsidiary. Additionally, Dr. Lal PathLabs will incorporate a wholly-owned subsidiary in Dubai, UAE. The board also approved the re-appointment of Dr. Arvind Lal as Executive Chairman and Mr. Rajit Mehta as a Non-Executive Independent Director. Dr. Reena Nakra and Dr. Saloni Khera were designated as Senior Management Personnel. M/s Ernst & Young LLP and M/s A.G. Agarwal & Associates were re-appointed as Internal Auditors and Cost Auditors, respectively. 82,750 Equity Shares were allotted under Employee Stock Option Plan 2022.

Dr. Lal PathLabs Ltd's Board of Directors approved the audited Standalone & Consolidated Financial Results for the quarter and financial year ended March 31, 2026. The board recommended a final dividend of ₹4/- per equity share (40% on face value of ₹10/- each) for FY26, with June 26, 2026, as the record date. Additionally, the company announced the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL), making it a Wholly Owned Subsidiary. Dr. Lal PathLabs also approved the incorporation of a new Wholly Owned Subsidiary, Dr. Lal PathLabs FZCO, in Dubai, UAE, signaling international expansion. Key management re-appointments include (Hony) Brig. Dr. Arvind Lal as Executive Chairman and Whole-Time Director, and Mr. Rajit Mehta as Non-Executive Independent Director. Dr. Reena Nakra and Dr. Saloni Khera were designated as Senior Management Personnel. The company also re-appointed M/s Ernst & Young LLP as Internal Auditors and M/s A.G. Agarwal & Associates as Cost Auditors for FY26-27, and allotted 82,750 Equity Shares under its ESOP 2022.

Dr. Lal PathLabs Ltd's Board of Directors approved the audited Standalone & Consolidated Financial Results for the quarter and financial year ended March 31, 2026. The board also recommended a final dividend of ₹4 per equity share (40% on face value of ₹10) for FY26, with June 26, 2026, as the record date. Key strategic decisions included the acquisition of a 100% stake in Shahbazkers Diagnostic Centre Private Limited, making it a wholly-owned subsidiary, and the incorporation of a new wholly-owned subsidiary, Dr. Lal PathLabs FZCO, in Dubai, UAE. Additionally, the board re-appointed Dr. Arvind Lal as Executive Chairman and Mr. Rajit Mehta as an Independent Director, designated Dr. Reena Nakra and Dr. Saloni Khera as Senior Management Personnel, and re-appointed internal and cost auditors for FY27. The company also allotted 82,750 equity shares under its ESOP 2022.

Dr. Lal PathLabs' Board of Directors met on April 30, 2026, to approve several key decisions. The board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. A final dividend of INR 4/- per equity share (40% on face value of INR 10/-) was recommended for FY26, with a record date of June 26, 2026. The company also announced the acquisition of 100% stake in Shahbazkers Diagnostic Centre Private Limited (SDCPL), making it a wholly-owned subsidiary. Furthermore, a new wholly-owned subsidiary, Dr. Lal PathLabs FZCO, will be incorporated in Dubai, UAE. The board re-appointed Dr. Arvind Lal as Executive Chairman and Mr. Rajit Mehta as Non-Executive Independent Director. Dr. Reena Nakra and Dr. Saloni Khera were designated as Senior Management Personnel. M/s Ernst & Young LLP and M/s A.G. Agarwal & Associates were re-appointed as Internal and Cost Auditors, respectively, for FY2026-27. Additionally, 82,750 equity shares were allotted under the Employee Stock Option Plan 2022.